PDL BioPharma, Inc (PDLI) and Humanized Antibodies
I don’t know what they are going to do in the long run, but right now they are sitting pretty collecting royalties! The most recent one I saw in the news is from Reuters “PDL Biopharma Inc to receive royalties on sales of Genetech’s Pertzumab (http://www.reuters.com/finance/stocks/PDLI.O/key-developments/article/2559431 ).
Second Opinion Weekly reported it upgraded as of 8 days ago to “Long”
and “Improving”. Thomson Reuters Stockreport gives it a positive rating of 9
out of a scale of 1-10. Interesting it
even has a dividend associated with it J
PDL BioPharma, Inc. (PDL) is a biotech company. PDL is engaged
in the management of antibody humanization patents and royalty assets, which
consist of its Queen et al. patents and license agreements with various
biotechnology and pharmaceutical companies. The Company receives royalties
based on sales of humanized antibody products marketed and may also receive
royalty payments on additional humanized antibody products launched before
final expiry in December 2014. It has entered into licensing agreements with
numerous entities that are independently developing or have developed humanized
antibodies under which it has licensed certain rights under its Queen et al.
patents to make, use, sell, offer for sale and import humanized antibodies. (Compliments of Scottrade)
-JR
(If you like e-books, check out http://www.wondersofkindle.com )
No comments:
Post a Comment